Mesoblast's long-term protection

By Dylan Bushell-Embling
Wednesday, 16 July, 2008

Mesoblast [ASX: MSB] has been granted a US patent through to 2019 for its Mesenchymal Precursor Cells [MPC], proprietary adult stem cells developed by Mesoblast and its sister company Angioblast Systems.

The patent ensures only Mesoblast and Angioblast can commercialise MPCs in the US.

MPCs were first identified in Australia, at the Hanson Institute in Adelaide. They are capable of repairing and regenerating a host of tissue types, including bone, cartilage, fat, blood vessels and heart muscle.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd